Biogen's innovative drug contracts are making a difference in Medicaid

21 October 2020

As the healthcare industry continues to face financial strains brought on by the COVID-19 pandemic, the USA’s Medicaid programs need ways to reduce drug spend.

Given this scenario, US biotech major Biogen (Nasdaq: BIIB) has teamed up with pharmacy benefit manager (PBM) Abarca to create the first outcomes-based contract to apply to Medicaid populations two years ago - and it is already providing critical relief to a program that receives one of the nation's lowest reimbursement rates.

Abarca, which is disrupting the industry with a new approach to technology and business practices released a new case study detailing a value-based agreement with Biogen for Avonex (interferon beta-1a) and Tecfidera (dimethyl fumarate), select products in the drugmaker's leading multiple sclerosis (MS) portfolio. Originally launched in 2017, this was the first publicly disclosed value-based agreement to serve Medicaid populations.

Alleviating financial strain for Medicaid clients

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK